Assignee
PERFUSE THERAPEUTICS INC
US·3 granted patents·6 pending applications·3 citations·filing 2022–2025
Top patents by PatentIndex Score
9 records- 0188US11738007B2Treatment of glaucoma using endothelin receptor antagonistsPERFUSE THERAPEUTICS INC·Filed 2022·Granted Aug 29, 2023·2 cites·11 claims
- 0283US2026076948A1Treatment of diabetic retinopathy using endothelin receptor antagonistsPERFUSE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0382US11786510B2Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseasesPERFUSE THERAPEUTICS INC·Filed 2022·Granted Oct 17, 2023·1 cites·4 claims
- 0479US2025099435A1Treatment of diabetic retinopathy using endothelin receptor antagonistsPERFUSE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0574US2024189288A1Treatment of glaucoma using endothelin receptor antagonistsPERFUSE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0670US11873279B2Compositions for treatment of ocular diseasesPERFUSE THERAPEUTICS INC·Filed 2022·Granted Jan 16, 2024·0 cites·20 claims
- 0769US2024109876A1Compositions for treatment of ocular diseasesPERFUSE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0864US2023414577A1Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseasesPERFUSE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0953US2024058265A1Treatment of ocular diseases using endothelin receptor antagonistsPERFUSE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →